#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Biliary cancer metastatic Complex regional pain syndrome Fibrosarcoma metastatic Medullary thyroid cancer Stevens-Johnson syndrome High-grade B-cell lymphoma Neuroendocrine carcinoma of the skin Ocular lymphoma Canavan disease Adrenoleukodystrophy Lymphoma Myelofibrosis Craniopharyngioma Niemann-Pick disease Pleural mesothelioma More trials…

    Learn about Rare Diseases

    Gaucher’s disease type I Rhabdomyosarcoma recurrent – Treatment Kearns-Sayre syndrome – Diagnostics Glycogen storage disease type I – Life with Disease Aicardi-Goutieres syndrome Glomerulonephritis membranous Lennox-Gastaut syndrome – Diagnostics Skin angiosarcoma – Life with Disease Lymphatic malformation – Basic Information Retinoblastoma – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Dsimc Lasofoxifene Dazucorilant Etelcalcetide Cyclophosphamide Adct-402 Miransertib Efmoroctocog Alfa RNK001 Bcmacp03 Vibosameran Cilastatin Dobutamine Triptorelin Pamoate Vindesine Sulfate Evx-01 Ambroxol Hydrochloride Ammonium Chloride LINAPRAZAN GLURATE Bi-1808 More therapies…

    Learn about Your Condition

    Pancreaticoduodenectomy Schizophrenia Amyotrophic lateral sclerosis Von Willebrand's disease Triple positive breast cancer Bipolar disorder Insulin resistance Fibrosarcoma Pathogen resistance Muscle hypertrophy Obliterative bronchiolitis Hot flush Castleman's disease Cough Sarcoidosis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Endometrial cancer

  • Study of NP137 with carboplatin, paclitaxel and pembrolizumab combination therapy for patients with advanced endometrial or cervical cancer who had prior chemotherapy

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Endometrial cancer
    • Cervix carcinoma
    Investigated Drugs:
    • Human Monoclonal Igg1 Antibody Against Netrin-1
    • Carboplatin
    • Paclitaxel
    France

  • Study of Giredestrant for Patients with Grade 1 Endometrial Cancer

    Not recruiting

    2 1 1
    Investigated Drugs:
    • Giredestrant
    Italy Poland

  • A Phase 1/2a Study of BNT142 Safety and Early Effectiveness in Patients with Advanced Solid Tumors Expressing CLDN6 Protein

    Not recruiting

    2 1 1
    Germany The Netherlands Spain

  • Study on the Effectiveness of Biomarker Staging Compared to Conventional Staging in Women with Early-Stage Endometrial Cancer Using Paclitaxel and Carboplatin

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Endometrial cancer
    Investigated Drugs:
    • Carboplatin
    • Paclitaxel
    Sweden

  • Study of Pembrolizumab and Lenvatinib for Patients with Advanced or Recurrent Endometrial Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Endometrial cancer
    Investigated Drugs:
    • Carboplatin
    • Lenvatinib
    • Paclitaxel
    Austria Belgium Germany Ireland Italy Poland +1

  • Study on Pembrolizumab, Lenvatinib, and Belzutifan for Patients with Liver, Colon, Pancreatic, Bile Duct, Gallbladder, Endometrial, or Esophageal Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Bile duct cancer
    • Colon cancer
    • Gallbladder cancer
    Investigated Drugs:
    • Belzutifan
    • Lenvatinib
    • Pembrolizumab
    Belgium France The Netherlands Spain
Previous Page
1 … 5 6 7 8 9
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!